NBSE
Price:
$0.378
Market Cap:
$1.42M
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for my...[Read more]
Industry
Biotechnology
IPO Date
2004-05-28
Stock Exchange
NASDAQ
Ticker
NBSE
According to NeuBase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -88.62%. This represents a change of 244.54% compared to the average of -25.72% of the last 4 quarters.
The mean historical ROE of NeuBase Therapeutics, Inc. over the last ten years is -102.65%. The current -88.62% ROE has changed -13.67% with respect to the historical average. Over the past ten years (40 quarters), NBSE's ROE was at its highest in in the June 2018 quarter at -3.17%. The ROE was at its lowest in in the September 2019 quarter at -237.15%.
Average
-102.65%
Median
-103.72%
Minimum
-270.08%
Maximum
-34.13%
Discovering the peaks and valleys of NeuBase Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 210.96%
Maximum Annual ROE = -34.13%
Minimum Annual Increase = -79.58%
Minimum Annual ROE = -270.08%
| Year | ROE | Change |
|---|---|---|
| 2022 | -147.61% | 210.96% |
| 2021 | -47.47% | -13.94% |
| 2020 | -55.16% | -79.58% |
| 2019 | -270.08% | 122.42% |
| 2018 | -121.43% | 16.50% |
| 2017 | -104.23% | 0.98% |
| 2016 | -103.22% | 188.58% |
| 2015 | -35.77% | 4.80% |
| 2014 | -34.13% | -68.21% |
| 2013 | -107.38% | 79.07% |
The current ROE of NeuBase Therapeutics, Inc. (NBSE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-83.41%
5-year avg
-128.35%
10-year avg
-102.65%
NeuBase Therapeutics, Inc.’s ROE is less than Oncternal Therapeutics, Inc. (61.57%), greater than OncoSec Medical Incorporated (-154.68%), less than Cassava Sciences, Inc. Warrant (0%), less than ASLAN Pharmaceuticals Limited (1.80%), greater than VBI Vaccines Inc. (-258.99%), greater than CohBar, Inc. (-58.44%), greater than Timber Pharmaceuticals, Inc. (-209.49%), less than 9 Meters Biopharma, Inc. (0%), greater than Impel Pharmaceuticals Inc. (-3099.99%), greater than Altamira Therapeutics Ltd. (-111.64%),
| Company | ROE | Market cap |
|---|---|---|
| 61.57% | $1.56M | |
| -154.68% | $596.00 | |
| 0% | $1.45M | |
| 1.80% | $777.12M | |
| -258.99% | $1.87M | |
| -58.44% | $1.19M | |
| -209.49% | $1.18M | |
| 0% | $145.00 | |
| -3099.99% | $956.00K | |
| -111.64% | $1.13M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuBase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NeuBase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NeuBase Therapeutics, Inc.'s ROE?
How is the ROE calculated for NeuBase Therapeutics, Inc. (NBSE)?
What is the highest ROE for NeuBase Therapeutics, Inc. (NBSE)?
What is the 3-year average ROE for NeuBase Therapeutics, Inc. (NBSE)?
What is the 5-year average ROE for NeuBase Therapeutics, Inc. (NBSE)?
How does the current ROE for NeuBase Therapeutics, Inc. (NBSE) compare to its historical average?